Quotient Wealth Partners LLC Has $570,000 Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Quotient Wealth Partners LLC decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 18.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,304 shares of the biopharmaceutical company’s stock after selling 1,846 shares during the period. Quotient Wealth Partners LLC’s holdings in Gilead Sciences were worth $570,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Private Wealth Management Group LLC bought a new stake in shares of Gilead Sciences during the fourth quarter worth approximately $29,000. CarsonAllaria Wealth Management Ltd. lifted its stake in shares of Gilead Sciences by 198.3% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 238 shares during the period. Sachetta LLC bought a new position in shares of Gilead Sciences in the 4th quarter worth $30,000. Palisade Asset Management LLC acquired a new stake in shares of Gilead Sciences during the first quarter worth $29,000. Finally, Gladius Capital Management LP bought a new stake in Gilead Sciences in the fourth quarter valued at about $34,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Up 1.1 %

Shares of NASDAQ GILD traded up $0.82 during mid-day trading on Friday, hitting $76.72. The company had a trading volume of 6,847,053 shares, compared to its average volume of 7,242,981. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. The firm has a 50-day simple moving average of $71.87 and a two-hundred day simple moving average of $70.23. The company has a market capitalization of $95.58 billion, a PE ratio of 213.11, a price-to-earnings-growth ratio of 3.37 and a beta of 0.18. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $87.86.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be paid a $0.77 dividend. The ex-dividend date of this dividend is Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a yield of 4.01%. Gilead Sciences’s dividend payout ratio is 855.56%.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of recent analyst reports. BMO Capital Markets upped their price target on Gilead Sciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Thursday, August 15th. Cantor Fitzgerald reissued a “neutral” rating and issued a $70.00 price target on shares of Gilead Sciences in a report on Friday, August 9th. TD Cowen dropped their price objective on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Friday, April 26th. Finally, Barclays decreased their target price on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research note on Monday, April 29th. Twelve research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $81.94.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $68.63, for a total transaction of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares in the company, valued at $6,614,559.40. The sale was disclosed in a filing with the SEC, which is available through this link. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the transaction, the insider now owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Johanna Mercier sold 5,490 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the sale, the insider now directly owns 114,979 shares of the company’s stock, valued at $8,506,146.42. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.